- Home
- MUJ vs AUTL Comparison
MUJ vs AUTL Comparison
Compare MUJ & AUTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MUJ
- AUTL
- Stock Information
- Founded
- MUJ 1998
- AUTL 2014
- Country
- MUJ United States
- AUTL United Kingdom
- Employees
- MUJ N/A
- AUTL N/A
- Industry
- MUJ Investment Bankers/Brokers/Service
- AUTL Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- MUJ Finance
- AUTL Health Care
- Exchange
- MUJ Nasdaq
- AUTL Nasdaq
- Market Cap
- MUJ 619.6M
- AUTL 433.8M
- IPO Year
- MUJ N/A
- AUTL 2018
- Fundamental
- Price
- MUJ $11.62
- AUTL $1.54
- Analyst Decision
- MUJ
- AUTL Strong Buy
- Analyst Count
- MUJ 0
- AUTL 5
- Target Price
- MUJ N/A
- AUTL $9.12
- AVG Volume (30 Days)
- MUJ 108.0K
- AUTL 2.8M
- Earning Date
- MUJ 01-01-0001
- AUTL 11-11-2025
- Dividend Yield
- MUJ 4.36%
- AUTL N/A
- EPS Growth
- MUJ N/A
- AUTL N/A
- EPS
- MUJ N/A
- AUTL N/A
- Revenue
- MUJ N/A
- AUTL $29,934,000.00
- Revenue This Year
- MUJ N/A
- AUTL $641.63
- Revenue Next Year
- MUJ N/A
- AUTL $109.21
- P/E Ratio
- MUJ N/A
- AUTL N/A
- Revenue Growth
- MUJ N/A
- AUTL 185.17
- 52 Week Low
- MUJ $9.74
- AUTL $1.11
- 52 Week High
- MUJ $11.70
- AUTL $4.69
- Technical
- Relative Strength Index (RSI)
- MUJ 60.05
- AUTL 46.56
- Support Level
- MUJ $11.50
- AUTL $1.58
- Resistance Level
- MUJ $11.62
- AUTL $1.72
- Average True Range (ATR)
- MUJ 0.08
- AUTL 0.11
- MACD
- MUJ -0.02
- AUTL -0.01
- Stochastic Oscillator
- MUJ 57.14
- AUTL 28.57
About MUJ Blackrock MuniHoldings New Jersey Quality Fund Inc.
BlackRock MuniHoldings New Jersey Quality Fund Inc is a non-diversified, closed-end management investment company. Its investment objective is to provide shareholders with current income exempt from U.S. federal income tax and New Jersey personal income taxes. The fund mainly invests in long-term, investment-grade municipal obligations exempt from U.S federal income taxes (except that the interest may be subject to the U.S. federal alternative minimum tax) and New Jersey personal income taxes, with remaining maturities of one year or more at the time of investment. The rest of its managed assets can be invested in securities that are rated below investment grade (or similar instruments), or invested directly in securities or synthetically through the use of derivatives.
About AUTL Autolus Therapeutics plc
Autolus Therapeutics PLC is a biopharmaceutical company developing next-generation programmed T-cell therapies for the treatment of cancer. The company's clinical-stage pipeline comprises Obe-cel (obecabtagene autoleucel), AUTO1/22, AUTO3, AUTO5, AUTO6, AUTO7 & AUTO8.